Tixagevimab–cilgavimab intramuscular PK
A two-compartment population PK model with intramuscular absorption for the long-acting antibody combination tixagevimab–cilgavimab and covariate-dependent bioavailability and disposition.
- Therapeutic
- Tixagevimab and cilgavimab, AZD7442, tixagevimab, cilgavimab, Evusheld, tixagevimab/cilgavimab
- Target
- SARS-CoV-2 Spike RBD
- Disease
- Ocular disease
Biological model
A two-compartment population PK model with intramuscular absorption for the long-acting antibody combination tixagevimab–cilgavimab and covariate-dependent bioavailability and disposition.
Intervention
Tixagevimab and cilgavimab, AZD7442, tixagevimab, cilgavimab, Evusheld, tixagevimab/cilgavimab
Biological focus
SARS-CoV-2 Spike RBD
Context
Ocular disease
Model details
A two-compartment population PK model with intramuscular absorption for the long-acting antibody combination tixagevimab–cilgavimab and covariate-dependent bioavailability and disposition.
Modeled states
- AUC ug day mlug*day/mL
Modeled dynamic state for auc ug day ml.
- A central mgmg
Modeled dynamic state for a central mg.
- A depot mgmg
Modeled dynamic state for a depot mg.
- A peripheral mgmg
Modeled dynamic state for a peripheral mg.
- elapsed time dayday
Modeled dynamic state for elapsed time day.
Key readouts
- Central antibody concentrationunknown
Model-derived readout for central antibody concentration.
- Peripheral antibody concentrationunknown
Model-derived readout for peripheral antibody concentration.
- Cumulative antibody exposureug*day/mL
Model-derived readout for cumulative antibody exposure.
- Effective absorption rateunknown
Model-derived readout for effective absorption rate.
- A central mgmg
Model-derived readout for a central mg.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
AZD7442 600 mg IM typical gluteal
How do dose, injection site, and patient covariates change tixagevimab–cilgavimab exposure? Explore this intervention regimen through Central antibody concentration, Peripheral antibody concentration, Cumulative antibody exposure, Effective absorption rate. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How do dose, injection site, and patient covariates change tixagevimab–cilgavimab exposure?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How do dose, injection site, and patient covariates change tixagevimab–cilgavimab exposure?
cl l day
Model parameter controlling cl l day.
Exploratory range around the default value.
5 evenly spaced values in L/day. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19Antimicrobial Agents and Chemotherapy
